Endostatins combined radiotherapy and chemotherapy in the treatment of advanced non-small cell lung cancer

Abstract

Objective To preliminary study clinical efficacy and toxicity of endostatin （ES） combined radiotherapy and chemotherapy in advanced non-small cell lung cancer （NSCLC）,and evaluate its effectiveness and safety.Methods We retrospectively reviewed 64 patients with Ⅲ B-Ⅳ stage NSCLC of Harbin Medical University Cancer Hospital from February 2009 to February 2012.The patients were divided into two groups：chemoradiotherapy group,39 patients and ES add chemoradiotherapy group,25 patients.The short-term effect,the total efficiency,median survival time,progression-free survival time and disease-free survival time were compared.Results The total effective rate of chemoradiotherapy group was 76.9%,while the total effective rate of ES add chemotherapy group was 84.0% （χ^2 =0.47,P =0.492）.Chemoradiotherapy group,compared to ES add chemotherapy group,the median survival time,median progression-free survival time,median disease-free survival time were 11.52 months vs 16.51 months （χ^2 =3.74,P =0.042）,7.32 months vs 10.37 months （χ^2 =5.32,P =0.025） and 5.21 months vs 7.57 months （χ^2 =4.56,P =0.035） respectively.The mainly adverse drug reactions were hematologic toxicity and gastrointestinal reactions,but there were no significant differences between the two groups; radiotherapy side effects mainly showed the grade 1 to 2 radiationinduced lung injury and radiation esophagitis （chemotherapy group had one case of grade 3 radiation-induced lung injury）,but also had no significant differences between the two groups.Conclusion ES combined chemoradiotherapy can achieve a better short-term clinical efficacy without increasing adverse effects of radiotherapy or chemotherapy in advanced non-small cell lung cancer. Key words: Carcinoma, non-small cell lung; Radiotherapy ; Chemotherapy, adjuvant; Endostatins